Voltammetric Determination of Candesartan Cilexetil in Its Cu(II) Complex and Application to Pharmaceutical FormulationsSÜSLÜ, Incilay; ÖZALTIN, Nuran; ALTINÖZ, Sacide et al.Journal of AOAC International. 2010, Vol 93, Num 2, pp 562-568, issn 1060-3271, 7 p.Article

Stability-Indicating Methods for the Determination of Candesartan Cilexetil in Bulk Drug and Pharmaceutical FormulationsISSA, Yousry M; HUSSIEN, Emad M; IBRAHIM, Magda M et al.Journal of AOAC International. 2013, Vol 96, Num 3, pp 580-586, issn 1060-3271, 7 p.Article

Thermodynamic analysis and correlation of solubility of candesartan cilexetil in aqueous solvent mixturesPENGLEI CUI; QIUXIANG YIN; JUNBO GONG et al.Fluid phase equilibria. 2013, Vol 337, pp 354-362, issn 0378-3812, 9 p.Article

Efficacité et tolérance du candésartan cilexetil 16 mg associé à 12,5 mg d'hydrochlorothiazide chez les patients présentant une hypertension artérielle essentielle non équilibrée par une association fixeVAÏSSE, B.La Lettre du cardiologue. 2004, Num 377, pp 32-35, issn 0761-5035, 4 p.Article

Efficacité du candesartan cilexetil chez les hypertendus diabétiques ou non diabétiques = Efficacy of candesartan cilexetil in hypertensive patients with or without diabetesEL FEGHALI, R; NISSE-DURGEAT, S; ASMAR, R et al.Archives des maladies du coeur et des vaisseaux. 2007, Vol 100, Num 8, pp 679-682, issn 0003-9683, 4 p.Conference Paper

A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapyCAMPBELL, M; SONKODI, S; SOUCEK, M et al.Clinical and experimental hypertension (1993). 2001, Vol 23, Num 4, pp 345-355, issn 1064-1963Article

Solubility of Candesartan Cilexetil in Different Solvents at Various TemperaturesPENGLEI CUI; QIUXIANG YIN; JUNBO GONG et al.Journal of chemical and engineering data (Print). 2011, Vol 56, Num 3, pp 658-660, issn 0021-9568, 3 p.Article

Efficacité du candésartan cilexétil chez les patients hypertendus diabétiques ou non. Méta-analyse des études cliniques randomisées en double aveugleLAVERGNE, A.La Lettre du cardiologue. 2007, Num 406, pp 38-40, issn 0761-5035, 3 p.Article

Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertensionOPARIL, S.The American journal of cardiology. 1999, Vol 84, Num 10A, pp 35S-41S, issn 0002-9149Article

Comparison of angiotensin II receptor blockers: Impact of missed doses of candesartan cilexetil and losartan in systemic hypertensionMANCIA, G; DELL'ORO, R; TURRI, C et al.The American journal of cardiology. 1999, Vol 84, Num 10A, pp 28S-34S, issn 0002-9149Article

Do pharmacologic differences among antihypertensive agents point to clinical benefits?MEREDITH, P.The American journal of cardiology. 1999, Vol 84, Num 10A, pp 22S-27S, issn 0002-9149Article

Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonistOTSUKA, M; TAKAHASHI, H; SHIRATORI, M et al.Thorax. 2004, Vol 59, Num 1, pp 31-38, issn 0040-6376, 8 p.Article

Candersartan cilexetil: from concept to clinicHOLLENBERG, Norman K; SEVER, Peter S.Blood pressure. 2000, Vol 9, issn 0803-7051, 61 p., SUP1Conference Proceedings

Putting the efficacy of candesartan cilexetil into perspective : a review of new comparative dataMALLION, J. M; BAGUET, J. P.Journal of human hypertension. 2000, Vol 14, pp S33-S41, issn 0950-9240, SUP2Conference Paper

A new class of diacidic nonpeptide angiotensin II receptor antagonists : Candesartan cilexetilNAKA, T; KUBO, K.Current pharmaceutical design. 1999, Vol 5, Num 6, pp 453-472, issn 1381-6128Article

Update on the clinical pharmacology of candesartan cilexetilGAVRAS, H.American journal of hypertension. 2000, Vol 13, Num 1, pp 25S-30S, issn 0895-7061, 2Conference Paper

Candesartan cilexetil in hypertension : Effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-aldosterone systemFRIDMAN, K. U. B; WYSOCKI, M; FRIBERG, P. R et al.Blood pressure. 1999, Vol 8, Num 4, pp 242-247, issn 0803-7051Article

Candesartan cilexetil: A review of its use in essential hypertensionMCCLELLAN, K. J; GOA, K. L.Drugs (Basel). 1998, Vol 56, Num 5, pp 847-869, issn 0012-6667Article

Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid stateAL OMARI, Alaa' A; AL OMARI, Mahmoud M; BADWAN, Adnan A et al.Journal of pharmaceutical and biomedical analysis. 2011, Vol 54, Num 3, pp 503-509, issn 0731-7085, 7 p.Article

Development and characterization of solid oral dosage form incorporating candesartan nanoparticlesNEKKANTI, Vijaykumar; PILLAI, Raviraj; VENKATESHWARLU, Vobalaboina et al.Pharmaceutical development and technology. 2009, Vol 14, Num 3, pp 290-298, issn 1083-7450, 9 p.Article

Candesartan Cilexetil Effectively Reduces Blood Pressure in Hypertensive ChildrenFRANKS, Amy M; O'BRIEN, Catherine E; STOWE, Cindy D et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 10, pp 1388-1395, issn 1060-0280, 8 p.Article

Long-term angiotensin II AT₁ receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARγZORAD, Stefan; DOU, Jing-Tao; BENICKY, Julius et al.European journal of pharmacology. 2006, Vol 552, Num 1-3, pp 112-122, issn 0014-2999, 11 p.Article

Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY studyNESBITT, Shawna D; JULIUS, Stevo; LEONARD, David et al.American journal of hypertension. 2005, Vol 18, Num 7, pp 980-985, issn 0895-7061, 6 p.Article

CandesartanGLEITER, Christoph H; JÄGLE, Christine; GRESSER, Ursula et al.Cardiovascular drug reviews (Print). 2004, Vol 22, Num 4, pp 263-284, issn 0897-5957, 22 p.Article

Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat: The effect of AT1-R blocker on the hepatic fibrosisTUNCER, Ilyas; OZBEK, Hanefi; UGRAS, Serdar et al.Experimental and toxicologic pathology (Print). 2003, Vol 55, Num 2-3, pp 159-166, issn 0940-2993, 8 p.Article